BioCryst Pharmaceuticals, Inc. (BCRX)

Market Cap	1.52B
Revenue (ttm)	557.51M
Net Income (ttm)	-35.71M
Shares Out	210.53M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	17.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,901,705
Open	7.23
Previous Close	7.19
Day's Range	7.15 - 7.34
52-Week Range	6.00 - 11.31
Beta	1.05
Analysts	Strong Buy
Price Target	19.55 (+171.53%)
Earnings Date	Nov 3, 2025

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 3, 1994
• Employees: 580
• Stock Exchange: NASDAQ
• Ticker Symbol: BCRX
• Website: https://www.biocryst.com

Financial Performance

In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.

Analyst Summary

According to 11 analysts, the average rating for BCRX stock is "Strong Buy." The 12-month stock price target is $19.55, which is an increase of 171.53% from the latest price.

Price Target

$19.55

(171.53% upside)

Analyst Consensus: Strong Buy